source
- Beam Therapeutics reports one-year data from early-stage AATD gene therapy trialBeam Therapeutics released new results from its early-stage gene-editing program targeting alpha-1 antitrypsin deficiency (AATD), a rare condition that can damage the lungs and liver. The data com…
- Anthropic hires corporate development lead to drive biopharma acquisitions and partnershipsAnthropic, the San Francisco AI company, posted a job for a corporate development lead focused on biopharma. The role will involve sourcing and executing acquisitions, investments and strategic pa…